| US Joint External Evaluation for Zoonotic Diseases |
Committee, Work group, Advisory group, or Task Force |
ASPR, CDC, FDA, HRSA, OS |
NIAID |
A Joint External Evaluation (JEE) is a voluntary, collaborative, multisectoral process to assess country capacities to prevent, detect and rapidly respond to public health risks whether occurring naturally or due to deliberate or accidental events. |
| US-Canada: Interagency Coordination on Wildfire Smoke and Health Research |
Committee, Work group, Advisory group, or Task Force |
CDC |
NIEHS |
Description to be updated |
| US-EU Bilateral Health Focus Group Meeting |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA |
NCI |
This group addresses new challenges around cancer, global health threats and strengthening the global health infrastructure |
| US-Israel White House-HHS Taskforce on Pandemic Preparedness and Innovation |
Committee, Work group, Advisory group, or Task Force |
ASPR, CDC |
NIBIB |
A partnership between the US and Israel on critical and emerging technologies to bring the cooperation between the countries to new heights including innovations for pandemic preparedness. |
| USCDI + Cancer |
Committee, Work group, Advisory group, or Task Force |
ONC, CDC, CMS, FDA, IHS |
NCI, OD/DPCPSI/ODSS |
This collaboration is designed to identify a core set of data elements that clinicians and researchers could use to (1) match patients to clinical trials; (2) document patients in cancer registries; and (3) identify patients who have experienced an immune-related adverse event. Additionally, this collaboration is designed to identify and mitigate the barriers clinical sites, EHR vendors, patients, etc. face when trying to implement this core set of data elements. We plan to release a draft set of data elements for public comment in July, 2024. |
| USCDI+ Cancer Trans-HHS Initiatives |
Committee, Work group, Advisory group, or Task Force |
CDC, CMS, FDA, ONC |
NCI, OD/DPCPSI/ODSS |
Also Collaboration Type: Resource DevelopmentThis trans-HHS collaboration began in 2024. In 2024, we finalized a core set of data elements that clinicians and researchers could use to document patients in cancer registries. The trans-HHS Team is developed a draft set of core data elements that clinicians and researchers could us to match patients to clinical trials and identify patients who have experienced an immune-related adverse event. This collaboration continues to identify and mitigate the barriers clinical sites, EHR vendors, patients, etc. face when trying to implement this core set of data elements. We plan to release a draft set of clinical trial matching and immune-related adverse event data elements for public comment in the Spring of 2025. |
| USG Interagency Cookstoves/Household Energy Meeting |
Committee, Work group, Advisory group, or Task Force |
CDC |
NIEHS |
Description will be updated |
| USG pandemic preparedness portfolio sharing group |
Committee, Work group, Advisory group, or Task Force |
ARPA-H, ASPR, BARDA |
NIAID |
Working group meetings bi-monthly to share portfolios and activities on vaccine and monoclonal antibody development for viruses with pandemic preparedness. |
| Using Real-time Prescription and Insurance Claims Data to Support the HIV Care Continuum |
Research Initiative |
CDC |
NIMH |
The Centers for Disease Control and Prevention (CDC) and the National Institute of Mental Health (NIMH) have established a cooperative agreement titled “Using Real-time Prescription and Insurance Claims Data to Support the HIV Care Continuum (CDC RFA-PS-19-003).” The purpose of the cooperative agreement is to develop, implement, and evaluate a “insurance-based data-to-care (D2C)” model. The insurance-based D2C model will start with Medicaid claims (diagnosis and procedure) to identify persons with diagnosed HIV, and then use real-time Medicaid claims data to determine whether these individuals have current antiretroviral (ARV) prescriptions. Persons with HIV who show lapsed ARV medications will receive a set of escalating adherence, retention, and re-linkage interventions. The research study will test the effectiveness of the approach (on viral suppression) as well as the cost-effectiveness of the approach. |
| Vaccines and Related Biological Products Advisory Committee (VRBPAC) |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIAID, OD/OSP |
VRBPAC reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products which are intended for use in the prevention, treatment, or diagnosis of human diseases, and, as required, any other products for which the Food and Drug Administration has regulatory responsibility. |